Pay in 4 interest-free payments of $5.43 Learn more
Ships within 48 hours · Estimated delivery Aug 28 - Sep 2
however, there remains an unmet need for new treatment options, as adequate symptom control is achieved in only 5260% of patients, and complete remission in 3644% [1]
The standard analytical framework begins with a drug-by-drug LOE calendar for each company in the coverage universe, mapping CoM expiration dates, secondary patent expiration dates, biosimilar reference product exclusivity end dates, and IRA negotiation eligibility dates against the companys revenue model
When discussing GLP-1 (glucagon-like peptide-1) receptor agonists, weight loss is often the first benefit that comes to mind
Ready to see if theres a study for you
US$ 25.73
:format(webp))
US$ 21.78
US$ 20.27
US$ 24.53
.png.jpg)
US$ 22.32
